Earhart R H
Oncology Medical Affairs, Rhône-Poulenc Rorer Pharmaceuticals, Inc, Collegeville, PA 19426, USA.
Semin Oncol. 1999 Oct;26(5 Suppl 17):8-13.
Docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) is the second member of the taxane class of cytotoxic agents to reach clinical use. The development of docetaxel was remarkably rapid, from the initial hemisynthesis in 1986 to worldwide filing for commercial use in 1994. Docetaxel is now approved in over 90 countries. As the use of docetaxel expands as a result of continuing preclinical and clinical investigation, better strategies for treatment of patients with cancer are emerging. This report reviews certain important new developments regarding docetaxel involving both its pharmacology and use in practice.
多西他赛（泰索帝；罗纳普朗克·罗瑞尔公司，宾夕法尼亚州学院村）是达到临床应用阶段的第二代紫杉烷类细胞毒性药物。多西他赛的研发速度极快，从1986年首次半合成到1994年在全球申请商业用途。目前多西他赛已在90多个国家获批。随着临床前和临床研究的不断推进，多西他赛的应用范围不断扩大，针对癌症患者的更佳治疗策略也不断涌现。本报告回顾了多西他赛在药理学和实际应用方面的某些重要新进展。
